Deep learning drills down on hyperlipidemia

Researchers in China have developed a deep learning algorithm able to diagnose hyperlipidemia—elevated levels of cholesterol, fats and triglycerides in the bloodstream—in both blood and urine specimens, potentially giving clinicians more information with less expense to the patient.  

Lead author Quan Zhang of Tianjin University and colleagues published their findings online in the journal Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.

The team built a neural network with an algorithm that, according to their study report, goes beyond hyperlipidemia classification to identify the condition’s parameters at the level of subtle but telling particulars.

For example, it can tell if patients have high blood sugar or markers of diabetes in their hemoglobin.

In the study, the algorithm made an accurate diagnosis 91.5% of the time.

The authors note their key achievement is advancing a previously proven deep learning algorithm such that it can now automatically extract all available clinical information from raw lab data, without human involvement.

Additionally, because the algorithm does not lose raw data, it may have the potential to find more diagnostic markers of different diseases, the authors explain.

“The proposed diagnostic method has a highly robust and accurate performance and can be used for tentative diagnosis,” the authors conclude. “It can automatically diagnose diseases by using human physiological parameters, thereby reducing labor cost, which results in effective improvement of clinical diagnostic efficiency.”

They added that, because their model uses parameters of hematology and urinology to diagnose hyperlipidemia rather than only using blood, it can give a more comprehensive diagnosis to guide clinicians’ treatment decisions.

The full study is available for downloading in PDF format.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.